Active pharmaceutical ingredient market predicted to hit $339 billion by 2030

By Jonathan Smith

- Last updated on GMT

© Getty Images
© Getty Images

Related tags API Active pharmaceutical ingredients Pharmaceutical drug Active ingredient

The increasing prevalence of chronic diseases could see the market for active pharmaceutical ingredients (APIs) growing by 7.5% per year, says a report by Prophecy Market Insights.

According to the report, the market for APIs was valued at $164.89 billion in 2020 and could soar to $339.08 billion by the year 2030.

APIs are the biologically active components of drug products in capsules, tablets and other delivery formats. This leads the API and pharmaceutical industries to be highly co-dependent and subject to shifts in the healthcare landscape.

One major trend in healthcare is the rising proportion of older adults in the population in many countries, accompanied by growth in chronic diseases such as cancer and cardiovascular diseases. This leads to higher spending on healthcare, and drives up demand for APIs and other pharmaceuticals, said the report.

The report also saw API manufacturing growing more advanced and gaining more government support, shoring up the growth of the space. Other driving factors include a growing number of strategic acquisitions & partnerships and the growing demand for complex biologic APIs.

One recent highlight by the report was the World Health Organization (WHO)’s  prequalification of an API developed by the Indian company Solara Active Pharma Sciences Limited. The API, named Flucytosine, is designed for use in the treatment of human immunodeficiency virus (HIV) infections and similar conditions.

The report also observed an increased outsourcing of API manufacturing to contract manufacturing organizations (CMOs). This coincides with reports in July​ of generics giant Teva Pharmaceuticals potentially looking for buyers for its active pharmaceutical ingredient (API) unit.

Other factors that are important to monitor for the API industry include increased scrutiny by regulatory authorities in the manufacturing process and the growing importance of emerging markets such as China and India in API manufacturing.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us